At the moment, Teizeild is indicated only for use in patients aged eight and over, but Sanofi has already filed for approval ...

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene ...

Under the terms of the J&J deal, Isomorphic will be responsible for in silico predictions and design, while the US group will ...

Pfizer will relinquish its stake in ViiV Healthcare in a deal valued at just over $2.1 billion that ramps up Shionogi's ...

The BIM-IOL is designed to be implanted during cataract surgery, tackling IOP while restoring vision, and SpyGlass is also ...

In a new pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Mohit Manrao, SVP, head of US oncology at ...

To get full control of C-CAR031, AZ is buying out AbelZeta's 50% share of the China development and commercialisation rights ...

GSK has agreed to pay $58 per RAPT share, with an upfront payment of $1.9 billion, that will give it global rights to ...

The use of AI in oncology has tremendous potential to improve many facets of cancer care, including diagnosis, drug discovery ...

Sun Pharma has downplayed a rumour that it is in talks to acquire women's health specialist Organon, after a report suggested ...

For decades, discovery has relied on "brute force" mass-screening – testing thousands of random compounds hoping one will ...

The Bio-Hermes-002 study, involving 1,000 volunteers aged over 60 in the UK, US and Canada, is using finger-prick testing to ...